tetano
Editor, Senior Moderator
Virulence
. 2020 Dec;11(1):805-810.
doi: 10.1080/21505594.2020.1780088.
Autophagy and SARS-CoV-2 Infection: Apossible Smart Targeting of the Autophagy Pathway
Shahla Shojaei[SUP] 1 [/SUP], Madhumita Suresh[SUP] 1 [/SUP], Daniel J Klionsky[SUP] 2 [/SUP], Hagar Ibrahim Labouta[SUP] 1 3 4 [/SUP], Saeid Ghavami[SUP] 3 5 6 7 8 9 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak resulted in 5,993,317 confirmed cases worldwide with 365,394 confirmed deaths (as of May 29[SUP]th[/SUP], 2020, WHO). The molecular mechanism of virus infection and spread in the body is not yet disclosed, but studies on other betacoronaviruses show that, upon cell infection, these viruses inhibit macroautophagy/autophagy flux and cause the accumulation of autophagosomes. No drug has yet been approved for the treatment of SARS-CoV-2 infection; however, preclinical investigations suggested repurposing of several FDA-approved drugs for clinical trials. Half of these drugs are modulators of the autophagy pathway. Unexpectedly, instead of acting by directly antagonizing the effects of viruses, these drugs appear to function by suppressing autophagy flux. Based on the established cross-talk between autophagy and apoptosis, we speculate that over-accumulation of autophagosomes activates an apoptotic pathway that results in apoptotic death of the infected cells and disrupts the virus replication cycle. However, administration of the suggested drugs are associated with severe adverse effects due to their off-target accumulation. Nanoparticle targeting of autophagy at the sites of interest could be a powerful tool to efficiently overcome SARS-CoV-2 infection while avoiding the common adverse effects of these drugs.
Keywords: Apoptosis; SARS-CoV-2; autophagy flux; drug targeting; macroautophagy; nanomedicine; nanoparticles.
. 2020 Dec;11(1):805-810.
doi: 10.1080/21505594.2020.1780088.
Autophagy and SARS-CoV-2 Infection: Apossible Smart Targeting of the Autophagy Pathway
Shahla Shojaei[SUP] 1 [/SUP], Madhumita Suresh[SUP] 1 [/SUP], Daniel J Klionsky[SUP] 2 [/SUP], Hagar Ibrahim Labouta[SUP] 1 3 4 [/SUP], Saeid Ghavami[SUP] 3 5 6 7 8 9 [/SUP]
Affiliations
- PMID: 32567972
- DOI: 10.1080/21505594.2020.1780088
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak resulted in 5,993,317 confirmed cases worldwide with 365,394 confirmed deaths (as of May 29[SUP]th[/SUP], 2020, WHO). The molecular mechanism of virus infection and spread in the body is not yet disclosed, but studies on other betacoronaviruses show that, upon cell infection, these viruses inhibit macroautophagy/autophagy flux and cause the accumulation of autophagosomes. No drug has yet been approved for the treatment of SARS-CoV-2 infection; however, preclinical investigations suggested repurposing of several FDA-approved drugs for clinical trials. Half of these drugs are modulators of the autophagy pathway. Unexpectedly, instead of acting by directly antagonizing the effects of viruses, these drugs appear to function by suppressing autophagy flux. Based on the established cross-talk between autophagy and apoptosis, we speculate that over-accumulation of autophagosomes activates an apoptotic pathway that results in apoptotic death of the infected cells and disrupts the virus replication cycle. However, administration of the suggested drugs are associated with severe adverse effects due to their off-target accumulation. Nanoparticle targeting of autophagy at the sites of interest could be a powerful tool to efficiently overcome SARS-CoV-2 infection while avoiding the common adverse effects of these drugs.
Keywords: Apoptosis; SARS-CoV-2; autophagy flux; drug targeting; macroautophagy; nanomedicine; nanoparticles.